XBP1 and neoplasm: Consistently, myeloma patients with higher amounts of XBP1s have a poorer overall survival (Bagratuni et al. 2010), and the growth of Xbp1-deficient tumor cells is impaired in xenograft models (Romero-Ramirez et al. 2004).